Cargando…

Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand

BACKGROUND: The nuclear hormone receptor RORγ regulates transcriptional genes involved in the production of the pro-inflammatory interleukin IL-17 which has been linked to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. This transcriptional activi...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcotte, Douglas J., Liu, YuTing, Little, Kevin, Jones, John H., Powell, Noel A., Wildes, Craig P., Silvian, Laura F., Chodaparambil, Jayanth V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888278/
https://www.ncbi.nlm.nih.gov/pubmed/27246200
http://dx.doi.org/10.1186/s12900-016-0059-3
_version_ 1782434837277179904
author Marcotte, Douglas J.
Liu, YuTing
Little, Kevin
Jones, John H.
Powell, Noel A.
Wildes, Craig P.
Silvian, Laura F.
Chodaparambil, Jayanth V.
author_facet Marcotte, Douglas J.
Liu, YuTing
Little, Kevin
Jones, John H.
Powell, Noel A.
Wildes, Craig P.
Silvian, Laura F.
Chodaparambil, Jayanth V.
author_sort Marcotte, Douglas J.
collection PubMed
description BACKGROUND: The nuclear hormone receptor RORγ regulates transcriptional genes involved in the production of the pro-inflammatory interleukin IL-17 which has been linked to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. This transcriptional activity of RORγ is modulated through a protein-protein interaction involving the activation function 2 (AF2) helix on the ligand binding domain of RORγ and a conserved LXXLL helix motif on coactivator proteins. Our goal was to develop a RORγ specific inverse agonist that would help down regulate pro-inflammatory gene transcription by disrupting the protein protein interaction with coactivator proteins as a therapeutic agent. RESULTS: We identified a novel series of synthetic benzoxazinone ligands having an agonist (BIO592) and inverse agonist (BIO399) mode of action in a FRET based assay. We show that the AF2 helix of RORγ is proteolytically sensitive when inverse agonist BIO399 binds. Using x-ray crystallography we show how small modifications on the benzoxazinone agonist BIO592 trigger inverse agonism of RORγ. Using an in vivo reporter assay, we show that the inverse agonist BIO399 displayed specificity for RORγ over ROR sub-family members α and β. CONCLUSION: The synthetic benzoxazinone ligands identified in our FRET assay have an agonist (BIO592) or inverse agonist (BIO399) effect by stabilizing or destabilizing the agonist conformation of RORγ. The proteolytic sensitivity of the AF2 helix of RORγ demonstrates that it destabilizes upon BIO399 inverse agonist binding perturbing the coactivator protein binding site. Our structural investigation of the BIO592 agonist and BIO399 inverse agonist structures identified residue Met358 on RORγ as the trigger for RORγ specific inverse agonism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12900-016-0059-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4888278
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48882782016-06-02 Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand Marcotte, Douglas J. Liu, YuTing Little, Kevin Jones, John H. Powell, Noel A. Wildes, Craig P. Silvian, Laura F. Chodaparambil, Jayanth V. BMC Struct Biol Research Article BACKGROUND: The nuclear hormone receptor RORγ regulates transcriptional genes involved in the production of the pro-inflammatory interleukin IL-17 which has been linked to autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. This transcriptional activity of RORγ is modulated through a protein-protein interaction involving the activation function 2 (AF2) helix on the ligand binding domain of RORγ and a conserved LXXLL helix motif on coactivator proteins. Our goal was to develop a RORγ specific inverse agonist that would help down regulate pro-inflammatory gene transcription by disrupting the protein protein interaction with coactivator proteins as a therapeutic agent. RESULTS: We identified a novel series of synthetic benzoxazinone ligands having an agonist (BIO592) and inverse agonist (BIO399) mode of action in a FRET based assay. We show that the AF2 helix of RORγ is proteolytically sensitive when inverse agonist BIO399 binds. Using x-ray crystallography we show how small modifications on the benzoxazinone agonist BIO592 trigger inverse agonism of RORγ. Using an in vivo reporter assay, we show that the inverse agonist BIO399 displayed specificity for RORγ over ROR sub-family members α and β. CONCLUSION: The synthetic benzoxazinone ligands identified in our FRET assay have an agonist (BIO592) or inverse agonist (BIO399) effect by stabilizing or destabilizing the agonist conformation of RORγ. The proteolytic sensitivity of the AF2 helix of RORγ demonstrates that it destabilizes upon BIO399 inverse agonist binding perturbing the coactivator protein binding site. Our structural investigation of the BIO592 agonist and BIO399 inverse agonist structures identified residue Met358 on RORγ as the trigger for RORγ specific inverse agonism. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12900-016-0059-3) contains supplementary material, which is available to authorized users. BioMed Central 2016-06-01 /pmc/articles/PMC4888278/ /pubmed/27246200 http://dx.doi.org/10.1186/s12900-016-0059-3 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Marcotte, Douglas J.
Liu, YuTing
Little, Kevin
Jones, John H.
Powell, Noel A.
Wildes, Craig P.
Silvian, Laura F.
Chodaparambil, Jayanth V.
Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title_full Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title_fullStr Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title_full_unstemmed Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title_short Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
title_sort structural determinant for inducing rorgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888278/
https://www.ncbi.nlm.nih.gov/pubmed/27246200
http://dx.doi.org/10.1186/s12900-016-0059-3
work_keys_str_mv AT marcottedouglasj structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT liuyuting structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT littlekevin structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT jonesjohnh structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT powellnoela structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT wildescraigp structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT silvianlauraf structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand
AT chodaparambiljayanthv structuraldeterminantforinducingrorgammaspecificinverseagonismtriggeredbyasyntheticbenzoxazinoneligand